abrdn Life Sciences Investors Fund maintains a buy rating, offering a compelling 11.6% yield and trading at a 9.58% NAV discount. HQL’s income-focused strategy relies on net realized gains, supporting ...

HQL has a long track record of success and I believe that the short term sentiment should not cloud the long term outlook of the fund. Healthcare spending is estimated to increase as the population ...

Find the latest Abrdn Life Sciences Investors (HQL) stock quote, history, news and other vital information to help you with your stock trading and investing.